CASEY SULLIVAN: Open Payments
NPI 1457015372 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$486 in 34 payments from 8 companies in 2025. Trend: 2023 $446 · 2024 $333 · 2025 $486
Food & beverage: $486
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 20 | $241 |
| AstraZeneca Pharmaceuticals LP | 4 | $78 |
| GENZYME CORPORATION | 2 | $49 |
| Electromed, Inc. | 4 | $34 |
| Viatris Specialty LLC | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Amgen Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
Products named: NUCALA, TRELEGY ELLIPTA, DUPIXENT, AIRSUPRA, TEZSPIRE, SMARTVEST, YUPELRI, Sunosi.
Industry payments across MD — which companies pay providers there.
